CD36 (thrombospondin receptor)

News alerts, weekly reports and conference planners

Entrez ID:

CD36 overexpression	HER2 Positive Breast Cancer	CD36 overexpression	HER2 Positive Breast Cancer	trastuzumab Resistant: B - Late Trials trastuzumab Resistant : B	trastuzumab Resistant: B - Late Trials trastuzumab Resistant : B
CD36 overexpression	Solid Tumor	CD36 overexpression	Solid Tumor	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3
CD36 overexpression	Glioblastoma	CD36 overexpression	Glioblastoma	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3
CD36 overexpression	Triple Negative Breast Cancer	CD36 overexpression	Triple Negative Breast Cancer	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3
CD36 overexpression + CD47 overexpression	Pancreatic Cancer	CD36 overexpression + CD47 overexpression	Pancreatic Cancer	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3
CD36 overexpression	Ovarian Cancer	CD36 overexpression	Ovarian Cancer	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3

Associations(6)